Table of Contents
CD80 | CD81 | CD82 | CD83 | CD84 | CD85 | CD85A | CD85B | CD85C | CD85D | CD85E | CD85F | CD85G | CD85H | CD85I | CD85J | CD85K | CD85L | CD85M | CD86 | CD87 | CD88 | CD89 | Diagrams / tables | Microscopic (histologic) imagesCite this page: Pernick N. CD80-89. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/cdmarkerscd80.html. Accessed March 31st, 2025.
CD80
- Also called B7-1, BB1
- T cells need 2 signals for activation; the first signal is antigen peptide presented on MHC class II through the T cell receptor
- The second (costimulatory) signal is delivered by CD80 or CD86, expressed on surface of antigen presenting cells, which interact with either CD28 or CD152 (CTLA-4)
- Has critical role in autoimmune, humoral and transplant responses
- Increased expression may cause excessive antigen presentation in fulminant hepatic failure, as an early step in its pathogenesis before the onset of tissue damage (Am J Pathol 1999;154:1711)
- Receptor for some adenovirus species (Virus Res 2006;122:144)
- No significant clinical use by pathologists
- Positive staining - normal: activated B cells, T cells, macrophages and dendritic cells
- Reference: OMIM: 112203 [Accessed 3 May 2021]
CD81
- Also called Target of an Anti-Proliferative Antibody (TAPA1)
- Receptor for Hepatitis C Virus E2 protein in B cells (J Virol 2006;80:8695)
- Also required for Plasmodium falciparum infectivity (Nat Med 2003;9:93)
- Upregulation on HIV1+ B cells may ultimately cause lymphoproliferative disorders (Clin Exp Immunol 2007;147:53)
- On B cells, is complexed with CD21, CD19 and Leu13; facilitates complement recognition
- Member of tetraspanin family; has close associations with major histocompatibility complex class I/II proteins
- Appears to promote muscle cell fusion and support myotube maintenance
- No significant clinical use by pathologists
- Positive staining - normal: lymphocytes, endothelial cells and epithelial cells
- Positive staining - tumors:
- HCV+ splenic diffuse large B cell lymphoma (Hum Pathol 2005;36:878)
- Burkitt’s lymphoma cell lines, neuroblastoma cell lines (J Pediatr Hematol Oncol 2000;22:20)
- Negative staining: erythrocytes, platelets and neutrophils
- Reference: OMIM: 186845 [Accessed 3 May 2021]
CD82
- Also called prostate cancer antimetastasis gene KAI1, kangai 1 (Chinese for anticancer)
- Metastasis suppressor gene
- Expression correlates with p53 expression
- Reduced expression of CD82 is associated with metastases / poor prognosis in carcinomas of:
- Bladder (Int J Urol 2004;11:74)
- Breast (Am J Pathol 1998;153:973, J Cancer Res Clin Oncol 2005;131:191)
- Colon (World J Gastroenterol 2004;10:2245)
- Endometrium (Clin Cancer Res 2003;9:1393)
- Larynx (Lin Chuang Er Bi Yan Hou Ke Za Zhi 2005;19:1065)
- Oral cavity (Clin Cancer Res 2002;8:828)
- Thyroid (Int J Mol Med 2004;14:517, Pathol Res Pract 2003;199:79)
- Expression reduces function of urokinase type plasminogen activator receptor (J Biol Chem 2005;280:14811)
- Uses by pathologists: possible use as prognostic marker (see above)
- Positive staining - normal: activated / differentiated hematopoietic cells, endothelial cells and epithelium
- Negative staining: erythrocytes
- Reference: OMIM: 600623 [Accessed 3 May 2021]
CD83
- Also called HB15
- May assist in antigen presentation or cellular interactions that follow lymphocyte activation
- Soluble form inhibits dendritic cell maturation and inhibits dendritic cell-mediated T cell proliferation (J Med Dent Sci 2006;53:85)
- Elevated serum levels seen in mantle cell lymphoma and CLL (Leuk Res 2004;28:237)
- Higher number of activated dendritic cells may be good prognostic factor for breast carcinoma (Int J Cancer 2003;104:92), cholangiocarcinoma (Hum Pathol 2004;35:881), colorectal liver metastases (Hum Pathol 2004;35:1392), gallbladder carcinoma (Oncol Rep 2005;14:353), gastric carcinoma-EBV+ (Am J Surg Pathol 2006;30:59) and advanced (Oncol Rep 2005;14:369)
- Uses by pathologists: marker for activated dendritic cells
- Positive staining - normal:
- Activated (mature) dendritic cells, activated T and B lymphocytes, monocytes / macrophages (transient) (Biochem J 2005;385:85)
- Langerhans cells, thymic epithelial cells, neutrophils during acute bacterial infection (Clin Exp Immunol 2002;130:501)
- Decidua (Am J Pathol 2000;157:159)
- Positive staining - disease:
- Infantile hemangioma endothelium (Am J Pathol 2006;168:621)
- Reed-Sternberg cells (Pathology 1997;29:294)
- Churg-Strauss syndrome myocarditis in inflammatory infiltrates (Arch Pathol Lab Med 2003;127:98)
- Reference: OMIM: 604534 [Accessed 3 May 2021]
CD84
- Also called Signaling Lymphocytic Activation Molecule 5 (SLAM5)
- Adhesion molecule that increases proliferative responses of activated T cells (J Immunol 2003;171:2485)
- Mediates platelet aggregation (Blood 2005;106:3028)
- No significant clinical use by pathologists
- Positive staining - normal:
- B cells, thymocytes (J Immunol 2001;167:3668)
- Mature T cells, memory T cells (high) (Tissue Antigens 2004;64:132)
- Monocytes / macrophages, platelets, dendritic cells, granulocytes and CD34+ hematopoietic progenitor cells (Exp Hematol 2003;31:798)
- Reference: OMIM: 604513 [Accessed 3 May 2021]
CD85
- Previously entire Immunoglobulin-like Transcript (ILT) family was clustered as CD85; now subclassified as CD85a to CD85m
- Also called Leukocyte Immunoglobulin-like Receptors (LIR) and Monocyte / Macrophage Immunoglobulin-like Receptors (MIR)
- CD85 itself is now called CD85J
- Family of immunoreceptors expressed on monocytes and B cells; lower levels on dendritic cells and NK cells
- Prevents NK / T cell killing and inhibits B cells by negative signaling receptors
- Note: some family members have activating functions (see specific family members below)
- References: Nat Immunol 2001;2:661, J Biol Chem 2006;281:19536
CD85A
- Also called ILT5, LIR3, LILRB3 (leukocyte immunoglobulin-like receptor subfamily, member 3), HL9
- Involved in NK mediated cytotoxicity
- An inhibitory receptor for MHC class I molecules
- No significant clinical use by pathologists
- Positive staining: myeloid cells, monocytes / macrophages, B cells, T cells (some), NK cells, basophils, eosinophils, dendritic cells (weak) (Blood 2004;104:2832, Proc Natl Acad Sci USA 2003;100:1174)
- Reference: OMIM: 604820 [Accessed 3 May 2021]
CD85B
CD85C
- Also called LIR8, LILRB5
- May act as receptor for class I MHC antigens
- No significant clinical use by pathologists
- Positive staining: NK cells
- Reference: OMIM: 604814 [Accessed 3 May 2021]
CD85D
- Also called ILT4, LIR2, MIR10, LILRB2
- Down regulates the immune response; involved in the development of tolerance
- Upregulated by HLA-G in antigen-presenting cells, NK cells and T cells (FASEB J 2005;19:662)
- Interacts with human leukocyte antigen A, B and G molecules and transmits negative signals that interfere with the activation of monocytes and dendritic cells (Hum Immunol 2004;65:700)
- Also competes with CD8A for binding to class I MHC antigens
- IL-10 renders dendritic cells hypostimulatory by upregulating cell surface CD85D and by inhibiting soluble CD85D in vitro; similar effect on endothelial cells (Eur J Immunol 2004;34:74, Eur J Immunol 2006;37:177)
- No significant clinical use by pathologists
- Positive staining: NK cells, T cells, monocytes / macrophages, dendritic cells, eosinophils (Proc Natl Acad Sci USA 2003;100:1174)
- Reference: OMIM: 604815 [Accessed 3 May 2021]
CD85E
- Also called ILT6, LIR4, LILRA3
- May act as soluble receptor for class I MHC antigens
- Homozygous deletions associated with multiple sclerosis (7% vs 4% of normals) (Genes Immun 2005;6:445)
- 85% of Japanese lack functional CD85E alleles (Hum Genet 2006;119:436)
- No significant clinical use by pathologists
- Positive staining: B cells, NK cells, peripheral blood monocytes, lung
- Reference: OMIM: 604818 [Accessed 3 May 2021]
CD85F
- Also called ILT11, LILRB7, LIR9
- May play a role in triggering innate immune responses (Blood 2003;101:1484)
- Membrane bound and secreted
- No significant clinical use by pathologists
- Positive staining: neutrophils, monocytes
- Negative staining: B cells, T cells, NK cells
- Reference: OMIM: 606047 [Accessed 3 May 2021]
CD85G
- Also called ILT7, LILRA4
- May act as receptor for class I MHC antigens
- No significant clinical use by pathologists
- Positive staining: plasmacytoid dendritic cells (J Exp Med 2006;203:1399)
- Negative staining: myeloid dendritic cells, other white blood cells
CD85H
- Also called ILT1, LIR7, LILRA2
- May act as receptor for class I MHC antigens
- Activating receptor for eosinophils (Proc Natl Acad Sci USA 2003;100:1174)
- No significant clinical use by pathologists
- Positive staining: basophils, myeloid and plasmacytoid dendritic cells (Blood 2004;104:2832)
- Negative staining: monocytes, T cells, B cells, NK cells
- Reference: OMIM: 604812 [Accessed 3 May 2021]
CD85I
- Also called LIR6, CD85i
- Note: since some biologists use lower case, CD85l [CD85L] may be confused with CD85i
- No significant clinical use by pathologists
- Positive staining: B cells, monocytes
- Negative staining: dendritic cells, NK cells, T cells
- References: OMIM: 604810 [Accessed 3 May 2021], J Immunol 2003;171:3056
CD85J
- Also called CD85, LIR1, ILT2, MIR7, LILRB1
- Transduces negative signals that prevent killing of MHC class I expressing cells
- Binds classical (HLA-A and HLA-B) and non-classical (HLA-G, HLA-E and HLA-F) MHC class I molecules
- Upregulated by HLA-G in antigen presenting cells, NK cells and T cells (FASEB J 2005;19:662)
- Receptor for CMV UL18 protein, which resembles MHC class I molecules (J Virol 2005;79:2251)
- No significant clinical use by pathologists
- Positive staining: B cells, monocytes, dendritic cells (low), T cells (some), NK cells (some)
- Reference: OMIM: 604811 [Accessed 3 May 2021]
CD85K
- Also called ILT3, LIR5, HM18, LILRB4
- Upregulated by HLA-G in antigen-presenting cells, NK cells and T cells (FASEB J 2005;19:662)
- Receptor for class I MHC antigens
- Recognizes broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles
- Involved in downregulation of immune response and development of tolerance, including transplants (Int Immunol 2004;16:1055)
- Aspirin use is associated with upregulation (Am J Transplant 2006;6:2046)
- No significant clinical use by pathologists
- Positive staining: dendritic cells (various), monocytes / macrophages, endothelial cells (Gene 2004;331:159, J Exp Med 1997;185:1743, Transplantation 2006;82:S30)
- Reference: OMIM: 604821 [Accessed 3 May 2021]
CD85L
- Also called ILT9, LILRA6P, LILRP1
- No significant clinical use by pathologists
- Reference: Eur J Immunol 1998;28:3959
CD85M
- Also called ILT10, LILRA5
- No significant clinical use by pathologists
- Positive staining: T cell subsets, monocytes, macrophages, neutrophils, dendritic cells and B lymphocytes (Washington State University)
CD86
- Also called B7-2
- T cells need 2 signals for activation: the first signal is antigen peptide presented on MHC class II through the T cell receptor
- The second (costimulatory) signal is delivered by CD80 or CD86, expressed on surface of antigen presenting cells, which interact with either CD28 or CD152 (CTLA-4)
- CD80 and CD86 appear to have opposing functions on regulatory T cells (J Immunol 2004;172:2778)
- Polymorphisms are associated with:
- Liver transplant acceptance (Transpl Immunol 2005;15:69)
- Systemic sclerosis (Int J Immunogenet 2006;33:155)
- Increased expression may cause excessive antigen presentation in fulminant hepatic failure as an early step in its pathogenesis before the onset of tissue damage (Am J Pathol 1999;154:1711)
- High circulating soluble levels are poor prognostic factor in myeloma (Br J Haematol 2006;133:165)
- Associated with severe asthma (Thorax 2004;59:870)
- Receptor for some adenovirus species (Virus Res 2006;122:144)
- Associated with H. pylori dependent early stage high grade MALT lymphoma of stomach (World J Gastroenterol 2005;11:4357)
- No significant clinical use by pathologists
- Positive staining - normal:
- B cells, thymocytes (J Immunol 2001;167:3668)
- Mature T cells, memory T cells (high, Tissue Antigens 2004;64:132)
- Monocytes / macrophages, platelets, dendritic cells, granulocytes and CD34+ hematopoietic progenitor cells (Exp Hematol 2003;31:798)
- Interdigitating dendritic cells in T zones of secondary lymphoid organs, Langerhans cells, peripheral blood dendritic cells, memory B cells, germinal center B cells, monocytes, endothelial cells, activated T cells
- Positive staining - disease:
- AML (29%) (Clin Cancer Res 2005;11:5708)
- Ulcerative colitis (100%) (Dig Dis Sci 2004;49:1738)
- Negative staining: immature dendritic cells
- Reference: OMIM: 601020 [Accessed 3 May 2021]
CD87
- Also called urokinase plasminogen activator receptor (uPA-R), PLAUR
- Membrane protein responsible for plasmin expression on cells
- Binds both the proprotein and mature forms of urokinase plasminogen activator
- Subject to negative feedback regulation by uPA, which cleaves it to an inactive form
- Implicated in metastasis - receptors for uPA and plasmin are found at leading edge of tumor cells; plasmin causes hydrolysis of extra-cellular matrix proteins in the path of cellular invasion
- Plasma levels of different soluble receptors are increased and predict mortality in HIV patients (J Acquir Immune Defic Syndr 2005;39:23)
- Pre-storage leukofiltration reduces transfusion reactions, perhaps due to reduction in soluble CD87 (Transfus Med 2004;14:305)
- Hypoxia and glucose deprivation may induce tumor invasion and metastases by upregulating CD87 (Exp Mol Med 2004;36:57, Exp Cell Res 2006;312:1685)
- Upregulated by dialysis and associated with clinical findings (Blood Purif 2006;24:236)
- Receptor for Group A Streptococcus (J Mol Biol 2005;350:27)
- No significant clinical use by pathologists
- Positive staining. - normal:
- T cells, NK cells, monocytes / macrophages, bands and neutrophils (Cytometry B Clin Cytom 2003;51:9)
- Endothelial cells, fibroblasts, basophils (J Immunol 2004;173:5739)
- Smooth muscle cells, keratinocytes, placental trophoblasts, hepatocytes
- Positive staining - tumors:
- Carcinomas of breast (Am J Pathol 2000;157:1219)
- Colon and prostate; prostatic nodal metastases (Hum Pathol 2006;37:1442)
- Melanoma, malignant and benign primary CNS tumors (Appl Immunohistochem Mol Morphol 2005;13:184)
- Negative staining: normal prostate, B / T cells and Hodgkin lymphoma (Am J Clin Pathol 1994;102:835)
- References: OMIM: 173391 [Accessed 3 May 2021], Wikipedia: Urokinase receptor [Accessed 3 May 2021]
CD88
- Also called C5R1, C5aR
- Receptor for C5a, the chemotactic and inflammatory peptide anaphylatoxin
- Stimulates chemotaxis, granule enzyme release and superoxide anion production
- May potentiate leukotriene production in lung and contribute to inflammation in asthma (Microbiol Immunol 2005;49:981)
- But also protects against airway hyperresponsiveness (J Clin Invest 2006;116:783)
- May also be involved in pathogenesis of COPD (Am J Respir Cell Mol Biol 2004;31:216)
- CD87 may mediate upregulation of CD88 in glomerular mesangial cells (J Cell Sci 2005;118:2743, Nephrol Dial Transplant 2000;15:1888)
- Reduced levels on neutrophils in HIV patients (J Infect Dis 2001;183:662)
- CD88 antagonists may be useful for treating complement mediated disorders (J Biomed Biotechnol 2006;2006:28945, J Immunol 2005;174:783)
- No significant clinical use by pathologists
- Positive staining - normal:
- Granulocytes, macrophages / monocytes, dendritic cells, mast cells (variable) (J Allergy Clin Immunol 2005;115:1162)
- Eosinophils (Eur J Immunol 1996;26:1560)
- Endothelial cells, hepatocytes, reactive astrocytes and microglia (Am J Pathol 1997;150:31)
- Keratinocytes in inflamed skin (Am J Pathol 1999;154:495)
- Positive staining - disease:
- Synoviocytes in arthritis (Chin Med J (Engl) 2003;116:1408)
- Mast cell sarcoma (Am J Surg Pathol 2003;27:1013)
- Reference: OMIM: 113995 [Accessed 3 May 2021]
CD89
- Also called FCAR, FCalphaR
- IgA Fc receptor, binds IgA and eliminates IgA coated targets
- Induces phagocytosis, degranulation, respiratory burst and killing of microorganisms
- Pathogenic group A and group B streptococci produce virulence factors that block the binding of IgA to CD89, inhibiting IgA-mediated immunity (J Biol Chem 2006;281:1389)
- No significant clinical use by pathologists
- Positive staining - normal: neutrophils, monocytes / macrophages, activated eosinophils, alveolar and splenic macrophages, interstitial dendritic cells
- Negative staining: mesangial cells (J Am Soc Nephrol 2000;11:241)
- Reference: OMIM: 147045 [Accessed 3 May 2021]
Microscopic (histologic) images
Images hosted on other servers: